spacer
home > pmps > spring 2019 > the impact of falsified medicines
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Impact of Falsified Medicines

In recent years, the number of falsified and counterfeit medications infiltrating the supply chain has become a growing problem for global health organisations and pharmaceutical manufacturers. Not only have there been cost implications, but there are also huge risks to patient safety.

The WHO references illegitimate medications as substandard and falsified medical products, with falsified medicines defined as “medical products that deliberately/ fraudulently misrepresent their identity, composition, or source” (1).

According to the WHO, about one in 10 pharmaceutical products in low and middle income countries are either substandard or falsified (2). The WHO also reported that, as of November 2017, “20 global medical product alerts and numerous regional warnings” had been issued, with “technical support provided in more than 100 cases” (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Neil Piper is an Auto ID expert and business consultant with over 25 years’ experience working predominantly in the retail and healthcare sectors. He is skilled in GS1 International Society of Blood Transfusion standards, barcode technologies (printing and scanning), radio frequency identification, electronic product code information services, and regulatory compliance (FMD, unique device identification, both FDA and EU medical devices regulation/in vitro diagnostic medical devices, UK Medicines and Healthcare products Regulatory Agency GS1 compliance, and more). Neil is currently redrafting Information Standards Board (ISB) 1077 and ISB 0108 standards to comply with NHS digital requirements. He has provided consultancy to numerous NHS trusts and pharmaceutical and medical device suppliers.
spacer
Neil Piper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development

MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: ‘The Art and Science of Dermal Formulation Development”. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
More info >>

White Papers

The current and future role of the medical oncologist in the professional care for cancer patients: a position paper by the European Society for Medical Oncology

European Society for Medical Oncology (ESMO)

  The number of cancer patients in Europe is rising and significant advances in basic and applied cancer research are making the provision of optimal care more challenging. The concept of cancer as a systemic, highly heterogeneous and complex disease has increased the awareness that quality cancer care should be provided by a multidisciplinary team (MDT) of highly qualified healthcare professionals. Cancer patients also have the right to benefit from medical progress by receiving optimal treatment from adequately trained and highly skilled medical professionals. Built on the highest standards of professional training and continuing medical education, medical oncology is recognised as an independent medical specialty in many European countries.
More info >>

 
Industry Events

The Universe of Pre-filled Syringes and Injection Devices

22-23 October 2019, The Swedish Exhibition & Congress Centre Gothia Towers Hotel

PDA’s Universe of Pre-filled Syringes and Injection Devices has become the must-attend meeting for everyone working in the field, and is now the world’s largest conference on this subject
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement